AAV vectors for hemophilia B gene therapy

Hengjun Chao, Christopher E. Walsh

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Adeno-associated viral (AAV) vector is attracting significant interest for use in gene therapy for genetic diseases, because of its unique and advantageous characteristics, compared to other currently available viral vectors. Eight natural serotypes of AAV have been identified, of which AAV serotype 2 is the one best characterized and most widely used in current gene delivery studies. The application of AAV serotype 2 in hemophilia B gene therapy is a promising development in gene therapy for genetic diseases such as hemophilia. Preliminary studies have demonstrated relation and distinction of host, genome sequences, replication, tropism, packaging of recombinant virions and cross-reactivity of neutralizing antibodies among different serotypes of AAV. This review summarizes the progress of studies in AAV serotypes and pertinent applications in hemophilia B gene therapy. The latest progress in gene delivery of coagulant factor IX (for hemophilia B) using AAV serotype vectors is described in detail.

Original languageEnglish
Pages (from-to)305-313
Number of pages9
JournalMount Sinai Journal of Medicine
Issue number5
StatePublished - Oct 2004


  • Adeno-associated virus
  • Gene therapy
  • Hemophilia B
  • Serotype


Dive into the research topics of 'AAV vectors for hemophilia B gene therapy'. Together they form a unique fingerprint.

Cite this